Benefit–risk assessment of vitamin D supplementation by Bischoff-Ferrari, H A et al.
University of Zurich
Zurich Open Repository and Archive
Winterthurerstr. 190
CH-8057 Zurich
http://www.zora.uzh.ch
Year: 2010
Benefit-risk assessment of vitamin D supplementation
Bischoff-Ferrari, H A; Dawson-Hughes, B; Shao, A; Hathcock, J; Giovannucci, E;
Willett, W C
Bischoff-Ferrari, H A; Dawson-Hughes, B; Shao, A; Hathcock, J; Giovannucci, E; Willett, W C (2010).
Benefit-risk assessment of vitamin D supplementation. Osteoporosis International, 21(7):1121-1132.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
Osteoporosis International 2010, 21(7):1121-1132.
Bischoff-Ferrari, H A; Dawson-Hughes, B; Shao, A; Hathcock, J; Giovannucci, E; Willett, W C (2010).
Benefit-risk assessment of vitamin D supplementation. Osteoporosis International, 21(7):1121-1132.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
Osteoporosis International 2010, 21(7):1121-1132.
1 
 
Benefit - Risk Assessment of Vitamin D Supplementation  
Accepted Osteoporosis International 2009 
1,2
Heike A. Bischoff-Ferrari, 
3
Andrew Shao, 
4
Bess Dawson-Hughes, 
3
John Hathcock, 
5
Edward Giovannucci, 
5
Walter C. Willett 
1
Centre on Aging and Mobility, University of Zurich, Switzerland; 
2
Dept. of Rheumatology and 
Institute of Physical Medicine, University Hospital Zurich, Switzerland; 
3
Council for 
Responsible Nutrition, Washington, DC, USA; 
4
USDA Human Nutrition Research Center on 
Aging, Tufts University, Boston, USA; 
4
Dept. of Nutrition, Harvard School of Public Health, 
Boston, MA, USA 
 
Address of correspondence: 
Prof. Heike A. Bischoff-Ferrari, MD, DrPH 
Director, Centre on Aging and Mobility 
University of Zurich 
Dept of Rheumatology 
Gloriastrasse 25 
8091 Zurich 
Switzerland 
Tel: +41-44-2552699 
 
Funding: Heike Bischoff-Ferrari is supported by a Swiss National Foundations Professorship 
Grant (PP00B-114864). This project was supported by an investigator initiated and unrestricted 
grant provided by DSM and by a Centre Grant of the University of Zurich and the Town of 
Zurich (Centre on Aging and Mobility).  
None of the authors have a conflict of interest. No disclosures.  
2 
 
ABSTRACT: 
Summary: The current intake recommendations of 200 to 600 IU vitamin D/d may be insufficient 
for important disease outcomes reduced by vitamin D.   
Introduction: To assess the benefit of higher dose and higher achieved 25-hydroxyvitamin D 
levels (25(OH)D) versus any associated risk. 
Results: Based on double-blind RCTs, 8 for falls (n=2426) and 12 for non-vertebral fractures (n= 
42,279), there was a significant dose-response relationship between higher dose and higher 
achieved 25(OH)D and greater fall and fracture prevention. Optimal benefits were observed at 
the highest dose tested to date for, 700 to 1000 IU vitamin D/d, or mean 25(OH)D between 75 to 
110 nmol/l (30-44 ng/ml). Prospective cohort data on cardiovascular health and colo-rectal 
cancer prevention suggested increased benefits with the highest categories of 25(OH)D evaluated 
(median levels between 75 and 110 nmol/l). In 25 RCTs, mean serum calcium levels were not 
related to oral vitamin D up to 100,000 IU /d or achieved 25(OH)D up to 643 nmol/l. Mean 
levels of 75 to 110 nmol/l were reached in most RCTs with 1800 IU to 4000 IU vitamin D/d 
without risk. 
Conclusion: Our analysis suggests that mean serum 25(OH)D levels of about 75 to 110 nmol/l 
provide optimal benefits for all investigated endpoints without increasing health risks.  These 
levels can be best obtained with oral doses in the range of 1800 to 4000 IU vitamin D/d; further 
work is needed, including subject and environment factors, to better define the doses that will 
achieve optimal blood levels in the large majority of the population. 
.  
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INTRODUCTION 
 
Voluminous data suggest that higher 25-hydroxyvitamin D (25(OH)D) serum concentrations are 
advantageous for chronic disease prevention. At present, strong evidence for causality is 
available for fracture[1] and fall endpoints[2], while promising epidemiologic and mechanistic 
studies suggest a key role of vitamin D in the preservation of cardiovascular health[3-6], and the 
prevention of cancer[7] and other common chronic diseases[8]. However benefits of vitamin D 
on falls, fractures, cardiovascular health, and cancer prevention that have been observed with 
higher 25(OH)D levels cannot be achieved in the large majority of individuals following current 
recommendations for vitamin D intake. The current adequate intake (AI) for vitamin D, as 
defined by the US Institute of Medicine (IOM), of 200 IU per day for adults up to 50 years of 
age (5 µg), 400 IU per day for adults between age 51 and 70 (10 µg), and 600 IU per day for 
those aged 70 years and over (15 µg) will achieve a serum 25(OH)D level of up to 50 or 60 
nmol/l for 2/3 of adults. 
 
This review draws together recent work by the authors and others on the benefits and risks of 
higher achieved 25(OH)D levels beyond 60 nmol/l to provide guidance in current efforts to 
define dose recommendations for vitamin D in the absence of  large randomized trials for non-
skeletal endpoints. We first examined double-blind RCT data for fall and fracture prevention, as 
well as mean serum calcium levels by dose and achieved 25(OH)D levels. Specifically, we 
assessed a dose-response relationship for these endpoints with established causality to explore 
whether the benefit of higher vitamin D dose and higher 25(OH)D levels is accompanied by an 
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increase in risk of hypercalcemia. Additionally, we assessed whether there were single case 
reports of hypercalcemia or nephrolithiasis from the same RCTs. 
We also evaluated dose-response relationships for non-skeletal outcomes of public health 
significance, including cardiovascular disease and cancer, especially colorectal cancer, in the 
context of case reports of hypercalcemia and documented 25(OH)D levels. Our overarching goal 
was to determine the optimal 25(OH)D level and vitamin D intake  that correspond to optimal 
health without risk of adverse effects.  
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METHODS 
 
In this review we summarize evidence for optimal serum 25(OH)D levels with respect to benefit 
and risk. The established benefits of higher vitamin D dose and higher achieved serum 25(OH)D 
levels were reduction in falls and fractures as summarized in two 2009 meta-analyses of double-
blind RCTs[1, 2]. The established risk of higher intakes of vitamin D or higher achieved serum 
25(OH)D level that we evaluated in the same RCT’s and any available RCTs of vitamin D 
supplementation and reported 25(OH)D status was hypercalcemia, evaluated as mean serum 
calcium level. We also examined case reports of hypercalcemia or nephrolithiasis in these trials.  
Additionally, we review benefits of vitamin D with the strongest evidence today from 
prospective epidemiological studies that are supported by strong mechanistic evidence, 
specifically reduction of cardiovascular disease (incident hypertension and cardiovascular 
mortality) and colo-rectal cancer. Weaker evidence of a beneficial effect of vitamin D exists for 
other diseases, including multiple sclerosis[9], tuberculosis[10], insulin resistance[11, 12], other 
cancers[13-16], osteoarthritis[17, 18] and prevalent hypertension [19-21], but these are not 
considered here.  For the assessment of risk in observational studies, we include data on serum 
calcium levels with any reported 25(OH)D level from case-reports of vitamin D intoxication. 
 
The risk assessment method used is a slight modification of the Institute of Medicine’s Tolerable 
Upper Intake Level (UL) method, as applied in a previous risk assessment on vitamin D by some 
of the current authors[22]. Our procedure uses the UL protocol exactly, except for a conservative 
selection of data so that no further correction for uncertainty is required[23].  Details of the entire 
literature up to that time were described in the previous risk assessment[22].   
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The benefit and risk that occur with increases in 25(OH)D concentration were placed in context 
with each other graphically using trend plots for each selected endpoint (decreased risk of falls 
and non-vertebral fractures) at different doses of vitamin D and achieved 25(OH)D levels.   
Given the limitations of using mean achieved serum calcium levels reported as a risk endpoint in 
trials of vitamin D supplementation, we also used individual serum calcium values in published 
case reports of hypercalcemia alleging vitamin D intoxication to compare with the prospective 
cohort data relating 25(OH)D concentrations to risks of cardiovascular disease and colorectal 
cancer.   
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RESULTS 
Benefit and risk data from RCTs  
Benefit of higher 25(OH)D levels on non-vertebral fracture prevention.  
In a recent meta-analysis the efficacy of oral supplemental vitamin D in preventing non-vertebral 
and hip fractures among older individuals was examined (age 65+)[1]. The analysis included 12 
double-blind randomized controlled trials (RCTs) for non-vertebral fractures (n=42,279; [1, 2, 
24-32]) and 8 RCTs for hip fractures (n = 40,886; [24, 25, 29, 30, 32-35]) comparing oral 
vitamin D with or without calcium with calcium or placebo. The pooled relative risk (RR) was 
0.86 (95% CI, 0.77-0.96) for prevention of non-vertebral fractures and 0.91 (95% CI, 0.78-1.05) 
for the prevention of hip fractures, but with significant heterogeneity for both endpoints. 
Including all trials, anti-fracture efficacy increased significantly with higher dose and higher 
achieved blood 25(OH)D levels for any non-vertebral fractures and hip fractures separately.  
Consistently pooling trials with a higher received dose of more than 400 IU/day (received dose 
of 482 – 770 IU per day) -  resolved heterogeneity and resulted in fracture reduction, while the 
lower received dose (340-380 IU per day) did not reduce fracture risk.  For the higher doses, the 
pooled RR was 0.80 (95% CI, 0.72 -0.89; n = 33,265 persons from 9 trials) for non-vertebral 
fractures and 0.82 (95% CI, 0.69 -0.97; n = 31,872 from 5 trials) for hip fractures. The higher 
doses reduced non-vertebral fractures significantly in community-dwelling (-29%) and 
institutionalized older individuals (-15%), and its effects were independent of additional calcium 
supplementation. Non-vertebral fracture prevention started with achieved 25(OH)D levels of at 
least 75 nmol/l in the treatment group. From left to right, Figure 1A indicates increased anti-
fracture efficacy with higher dose, and Figure 1 B with higher achieved 25(OH)D levels in the 
treatment group (meta-regression analyses by dose: p-value = 0.003; by achieved 25(OH)D 
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level: p-value = 0.04; these values are based on 12 trials for dose and 10 trials with measured 
25(OH)D levels). From Figure 1A optimal fracture prevention occurred in trials with achieved 
mean 25(OH)D levels of approximately 75 to 110 nmol/l.  
This threshold of optimal non-vertebral fracture prevention is supported by a large cross-
sectional and population-based study that showed a positive dose-response association between  
higher 25(OH)D levels and hip bone density both in younger and older adults [36]. In the 
regression plots, higher serum 25(OH)D levels were associated with higher hip bone density 
throughout the reference range of 22.5 to 94 nmol/l in all subgroups by age and ethnicity. In 
younger whites and younger Mexican Americans, higher 25(OH)D levels were associated with 
higher hip bone density even beyond 100 nmol/l. 
 
Benefit of higher 25(OH)D levels on fall prevention 
In another meta-analysis the efficacy of oral supplemental vitamin D in preventing falls among 
older individuals (age 65+) was examined[2]. Only double-blind RCTs with prospective fall 
assessment were considered (falls were assessed as a primary or secondary endpoint, authors 
stated how falls were defined and assessed, and falls were assessed over the whole trial period). 
The analysis included 8 double-blind RCTs (n = 2426; [31, 37-43]) comparing oral vitamin D 
with or without calcium with calcium or placebo. The pooled relative risk (RR) was 0.87 (95% 
CI, 0.77-0.99) for prevention of falls, but with significant heterogeneity (Q-test: p = 0.05). 
Heterogeneity was observed for dose of vitamin D (low-dose: < 700 IU / day versus higher dose: 
700 to 1000 IU / day; p-value 0.02) and achieved 25(OH)D level (< 60 nmol/l versus  60 
nmol/l; p-value = 0.005). Higher dose supplemental vitamin D reduced fall risk by 19% (pooled 
relative risk (RR) = 0.81; 95% CI, 0.71-0.92; n = 1921 from seven trials). Falls were not reduced 
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by low dose supplemental vitamin D (pooled RR = 1.10, 95% CI, 0.89-1.35 from 2 trials) or by 
achieved serum 25(OH)D concentrations less than 60 nmol/l (pooled RR = 1.35, 95% CI, 0.98-
1.84). Fall prevention increased with higher dose (Figure 2A), and with higher achieved 
25(OH)D levels in the treatment group (Figure 2 B). Similar to non-vertebral fracture prevention 
described above, optimal fall prevention appeared to occur in trials with achieved mean 
25(OH)D levels of approximately 75 to 100 nmol/l(see Figure 2 B).  
This threshold of optimal fall prevention is supported by a large cross-sectional and population-
based study that showed a dose-response association between  higher 25(OH)D levels and better 
lower extremity function in older adults[44]. For both tests, performance speed continued to 
increase throughout the reference range of 25(OH)D (22.5 to 94 nmol/l) with most of the 
improvement occurring in 25(OH)D levels going from 22.5 to approximately 60 nmol/l. Further 
improvement was seen in the range of 60-94 nmol, but the magnitude was less dramatic. 
 
Levels of 25(OH)D in relation to change in mean serum calcium levels and hypercalcemia 
in  controlled trials 
We included the published 22 RCTs involving an oral dose (either D2 or D3) of greater than or 
equal to 1800 IU/day (or the equivalent in weekly, monthly, bolus doses, etc…), and in which 
both mean serum calcium and serum 25(OH)D were reported (Appendix; Table 1; [45-66]).  The 
reason for this cut off stems from the purpose of conducting a risk assessment for doses close to 
or greater than the IOM identification of 2000 IU as the Tolerable Upper Intake level (UL). In 
addition, in Figure 1 A and B, we plotted mean serum calcium levels from 5 double-blind RCTs 
that reported serum calcium levels after vitamin D supplementation along with the fall and 
fracture endpoints[29, 34, 38, 43, 67]. The vitamin D doses in these 5 trials ranged from 400 to 
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800 IU vitamin D per day. In Figure 1 A and B a total of 28 data points for mean calcium levels 
are depicted (2 data points stem from one trial for the report by type of dwelling[45]). In Figure 
1 A and B we drew a trendline based on this series of mean serum calcium levels. The horizontal 
trendline indicates that mean serum calcium levels did not increase with higher doses of vitamin 
D up to 100,000 IU per day (Figure 1 A) or with higher achieved 25(OH)D levels up to 643 
nmol/l (Figure 1B). The one trial with 100,000 IU dose of vitamin D per day had a very short 
duration of 4 days, while the other trials ran for at least one half-life of vitamin D, which is 3 to 6 
weeks. We address treatment duration in more detail later in the results section. Notably, in none 
of the trials was there a shift of mean serum calcium levels above the normal physiologic range 
(> 2.6 mmol/l) with vitamin D treatment. However, in the Honkanen et al. trial depicted in 
Figure 1A and B, there was an increase in mean serum calcium levels above 2.6 nmol/l in the 
institutionalized control group receiving calcium supplementation without vitamin D[45]. Not 
shown in Figure 1 is one controlled trial with a report of increased mean calcium levels above 
2.6 nmol/l as the trial did not measure 25(OH)D levels: the Narang et al. 1984 trial randomized 
30 healthy adults to 0, 400, 800, 1200, 2400, 3800 IU/day for 90 days and observed a significant 
increase in mean serum calcium levels in the two highest dose groups (2.62 and 2.82 mmol/l, 
respectively)[68].  The limitations of the Narang study include the location and population 
studied (India), the small sample size (n = 5 per group) and failure to measure serum 25(OH)D 
levels.  Finally, the finding of a significant increase in mean serum calcium levels at these doses 
has not been replicated in any subsequent published RCT.   
 
For reports of single cases of hypercalcemia, two RCTs of the 28 RCTs identified and depicted  
in Figure 1 A and B reported single cases where serum calcium levels rose above the normal 
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range (> 2.6 mmol/l):  (1) Talwar et al. 2007 with a daily dose of 2000 IU plus 1500 mg calcium 
supplementation in healthy black women treated for 12 months[48]; (2) Maalouf et al. 2008 with 
a daily dose of 2000 IU vitamin D in healthy Libanese adolescents treated for 12 months[47].  In 
the Talwar study 6 isolated incidents of mild hypercalcemia occurred in 8 clinical visits over 3 
years in 208 women. The authors report that all 6 cases of hypercalcemia resolved on the repeat 
fasting sample.  In the Maalouf study, hypercalcemia ranging from 2.7 to 2.77 nmol/l was 
described in 7 of 340 adolescents, 5 cases in the placebo group, 1 with 1400 IU vitamin D per 
week (equivalent to 400 IU per day), and one with 14, 000 IU vitamin D per week (equivalent to 
2000 IU per day).  
Of all controlled trials with vitamin D, an increased incidence of nephrolithiasis occurred only in 
the very large Women’s Health Initiative (WHI) trial (involving 400 IU vitamin D plus 1000 mg 
of calcium per day).  [24].  
 
We also identified 10 uncontrolled trials with oral vitamin D supplementation at doses of at least 
1800 IU per day and reported serum calcium levels after treatment (Appendix; Table 2; [69-77]). 
Of these, two reported an increase in mean serum calcium levels above the normal range or 
single cases with hypercalcemia: (1) Tucci et al reported a mean serum calcium level that 
exceeded 2.6 mmol/l at baseline and after administration of 7120 IU vitamin D per day  in adult 
primary hyperparathyroidism patients [74].; mean serum calcium levels were 2.73 mmol/l at 
baseline and after treatment, However, the authors also reported of 2 patients in whom serum 
calcium levels rose from 2.8 to 3.03 mmol/l and from 2.83 to 3.05 mmol/l, respectively. (2) 
Restorff et al. reported of 2 single cases of mild hypercalcemia (2.69 mmol/l) at 3 months  and 
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normal levels at 6 months in one small uncontrolled trial of 33 elderly rheumatology patients 
with severe vitamin D deficiency treated with a single oral dose of 300,000 IU vitamin D3[76]. 
 
The other remaining clinical trials we identified (both controlled and uncontrolled) did not assess 
serum calcium and/or serum 25(OH)D [30, 78-81].  In some instances serum calcium was 
assessed, but only the observation of a lack of hypercalcemia or no significant change in serum 
calcium was reported ([82-89].  Vitamin D daily (or equivalent) oral doses ranged in these trials 
from 2000 – 300,000 IU. 
 
Benefit and risk data from observational data 
Data from epidemiologic studies on the RR of incident hypertension[4], all-cause[90] and 
cardiovascular[90] mortality and colorectal cancer [91] based on categories of median 25-
hydroxyvitamin D levels are presented in Figure 2. For all-cause and cardiovascular mortality 
we included a population-based prospective cohort study (National Health and Nutrition Survey 
III) controlling for age, sex, race/ethnicity, season of blood-draw, income, region, body mass 
index, physical activity, smoking status, cigarette pack years, asthma, chronic obstructive 
pulmonary disease, and renal function in community-dwelling individuals age 65 and older [90]. 
Consistent findings have been reported from a large cohort of patients undergoing 
angiography[3] and a second report within the National Health and Nutrition Survey III 
including younger individuals age 20 and older [92], which confirmed an optimal 25(OH)D 
range of  100 to 120 nmol/l for all-cause mortality.  
For colorectal cancer, we included a quantitative meta-analysis of 5 studies [91]. For all non-
skeletal endpoints of public health significance illustrated in Figure 2, there was a dose-response 
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of better health status with higher median 25(OH)D levels. By visual inspection, the desirable 
median serum 25(OH)D level to be achieved for all non-skeletal endpoints included in this report 
was approximately 100 nmol/l. 
 
The solid grey diamonds in Figure 2 relate to 24 case-reports of hypercalcemia allegedly from 
vitamin D intoxication with corresponding 25(OH)D levels (Appendix; Table 3[93-115]). Only 2 
out of 24 cases with hypercalcemia were reported at 25(OH)D levels below 240 nmol/l 
25(OH)D[93, 110], one of which involved a 85 year old woman who reported consuming 400 
IU/d vitamin D and had a  25(OH)D of 62 nmol/l[93], the other in a newly arrived international 
10 months-old adoptee[110].  These appear to be aberrant cases which have not been replicated 
in the literature.  Extending to a cut-off of 400 nmol/l 25(OH)D a third case with hypercalcemia 
occurred with 25(OH)D levels of 250 nmol/l.  The third case occurred in a 77 year old woman 
with primary hyperparathyroidism who received 50,000 IU D2 daily instead of weekly for 2 
years with a 25(OH)D level of 250 nmol/l[96]. All other cases of hypercalcemia (n = 21) were 
reported at 25(OH)D levels of 525 to 2070 nmol/l, clearly outside a target range of 75 to 110 
nmol/l for optimal health illustrated in Figures 1 B and 2.  There are also case reports in the 
published literature describing individual circumstances where extremely high vitamin D doses 
have been claimed (ranging from 50,000 IU to 150,000 IU/day vitamin D2 or D3), verified by 
correspondingly high serum 25(OH)D values (ranging from 107 to 1126 nmol/l), but serum 
calcium levels were reported to not exceed the threshold for hypercalcemia (2.6 mmol/l)[116] 
[98, 117]. 
Summary of serum 25(OH)D response to oral vitamin D 
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In summary, the data for fall and fracture prevention as well as epidemiologic data on 
preservation of cardiovascular health, general mortality and colorectal cancer prevention suggest 
that serum 25(OH)D levels close to 100 nmol/l are desirable and carry no risk of hypercalcemia, 
as evidenced by controlled trials. Figure 3 illustrates 25(OH)D response to vitamin D doses 
between 200 to 1000 IU per day in fall and fracture trials, and 1800 IU to 7600 IU from other 
RCTs included in Figure 1 A and B . With a supplement equal to the AI for young adults of 400 
IU per day, data from 3 large RCTs achieved a mean increase in 25(OH)D levels to 56.7 nmol/l 
(range: 44 to 64 nmol/l) after a mean treatment duration of 653 days leaving more than 50% of 
individuals below the desirable target range of at least 75 nmol/l for fall and fracture reduction 
and with very limited chances to reach an optimal range close to 100 nmol/l.  With a supplement 
of 800 IU vitamin D per day, a recommendation 200 IU higher than the highest of the AI values 
for the oldest segment of the population, tested in 9 RCTs for a mean duration of 697 days 
resulted in a mean increase in 25(OH)D levels to 75 nmol/l (range: 60 to 105 nmol/l) after a 
mean treatment duration of 697 days (range: 56 to 1680 days) leaving about 50% of individuals 
below the desirable target range of at least 75 nmol/l for fall and fracture reduction and a small 
chance to reach an optimal range close to 100 nmol/l. Most healthy younger and older adults 
reached the target range of 75 to 110 nmol/l with 1800 IU to 4000 IU vitamin D3 per day treated 
for at least 42 days.  
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DISCUSSION 
Recommendations for consumption of a nutrient are a function of the Tolerable Upper Intake 
Level (UL) and the Recommended Dietary Allowances (RDA) or for some nutrients the 
Adequate Intake (AI).  For vitamin D, the necessary evidentiary basis for a RDA (i.e., the mean 
requirement and an estimate of variance) could not be identified by the Institute of Medicine 
(IOM) in 1997 and, instead, an AI was identified[118]. The AI is an estimated average intake by 
a group or groups of healthy people and may not reflect the intake needed to achieve a specific 
health outcome. In order to assess whether a higher vitamin D intake resulting in higher achieved 
25(OH)D levels is desirable and safe, we performed a dose-response evaluation bringing 
together data on benefits and risks of higher doses and higher achieved 25(OH)D levels. 
 
Based on endpoints with established causality from double-blind RCTs as well as epidemiologic 
data on cardiovascular health (incident hypertension, general mortality and cardiovascular 
mortality) and colorectal cancer prevention, our review suggests that the target range of 
25(OH)D level for these benefits is not accompanied by increased risk of hypercalcemia. 
Notably, all endpoints evaluated for dose-response with higher 25(OH)D levels point to a similar 
target range of at least 75 nmol/l and better approximately 100 nmol/l. 
Based on our benefit assessment, the current intake recommendations for vitamin D using the AI 
are insufficient to bring a majority of individuals up to at least 75 nmol/l 25(OH)D and close to 
100 nmol/l. Revising recommendations towards a higher dose of vitamin D thus needs an 
assessment of risk with vitamin D supplementation doses that may bring most of the population 
into the target range of 75 to 110 nmol/l. This 25(OH)D range was reached in most trials with 
1800 to 4000 IU vitamin D per day. Likely, individuals who start with lower 25(OH)D levels 
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will need a supplementation dose at the higher end of this range[59, 119]. Most vulnerable to low 
vitamin D levels are elderly [120, 121], individuals living in northern latitudes with prolonged 
winters and thus low UVB exposure [122, 123], obese individuals[124], and African Americans 
of all ages[36, 125, 126].  
In our current risk assessment, hypercalcemia was chosen as the critical effect, the adverse effect 
occurring at the lowest intake. There were no increases in mean calcium levels with higher 
vitamin D intakes tested in controlled trials up to 100,000 IU per day. For single cases of 
hypercalcemia from RCTs, there were cases of mild hypercalcemia from 2 of 28 studies, which 
resolved on repeating fasting samples in one study[48], and were more frequent in the placebo 
group in the second study[47]. 
When we extend our assessment of risk to include case reports of hypercalcemia and associated 
25(OH)D levels, hypercalcemia occurred in 22 of 24 cases beyond 240 nmol/l 25(OH)D. Of the 
two cases that occurred at serum levels below 240 nmol/l 25(OH)D, one case involved a 85 year 
old woman who reported consuming 400 IU/d vitamin D and had a 25(OH)D of 62 
nmol/l[93].The other was described in a newly arrived adoptee with unknown vitamin D 
exposure[110].  Notably, 21 of 24 cases of hypercalcemia occurred with 25(OH)D levels beyond 
400 nmol/l.   
The only RCT that documented an increased risk of nephrolithiasis was the Women’s Health 
Initiative (WHI), which tested 400 IU vitamin D in combination with 1000 mg of calcium 
(hazard ratio,1.17; 95 percent confidence interval, 1.02 to 1.34)[24].  Whether this was the only 
trial large enough to detect a small risk of nephrolithiasis with vitamin D supplementation or 
whether this was caused by the substantial calcium supplement intake taken in combination with 
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the vitamin D and/or the additional calcium and vitamin D supplements taken by the majority of 
participants outside the study protocol in the WHI trial is unclear. However, the low dose 
vitamin D used in the WHI argues against a causal role of the increased risk of nephrolithiasis. 
Based on epidemiologic data, a higher vitamin D intake was not independently associated with 
nephrolithiasis in one large cohort[127] consistent with findings from a recent study of 18 
healthy postmenopausal women with vitamin D deficiency where vitamin D supplementation did 
not increase urinary calcium excretion [128]. On the other hand, calcium supplementation was 
associated with a 20% increased risk of nephrolithiasis in the Nurses Health Study I[129], 
although not in a cohort of younger women [129]. Overall, the data are insufficient to identify 
nephrolithiasis as the critical effect. 
 
The issue of vascular calcification in persons on renal dialysis has also been addressed in detail 
in the 2007 risk assessment and are not addressed in this review[22].  However, reports in the 
literature continue to be restricted to extremely high doses of vitamin D3 or administration of the 
active hormonal form, 1,25(OH)2D3 and/or related analogues, and most of these reports are in 
animals, not humans. There continues to be no credible evidence to support the notion that oral 
vitamin D doses up to and even exceeding 10,000 IU per day are associated with vascular 
calcification in humans, including dialysis patients, and there is no basis for identifying vascular 
calcification as the critical effect. 
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There are several limitations to the evaluation of dose-response relationship through a trend-plot 
approach using mean serum calcium levels after treatment in trials that also report 25(OH)D 
levels. This approach may miss single cases of hypercalcemia. To address this problem we also 
assessed the report of hypercalcemia in all available controlled trials without evidence of an 
increased risk with higher achieved 25(OH)D levels up to 640 nmol/l or a daily dose of 100,000 
IU vitamin D from controlled trials. Also, in theory, a direct comparison of the benefit and risk 
resulting from consumption of vitamin D would require a common metric.  As an indicator of 
risk, we used increases in mean or individual case serum calcium level (a continuous variable, 
within the range permitted by physiological controls), while the benefit was assessed with the 
endpoints fall and fracture prevention, as well as endpoints of cardiovascular health and 
colorectal cancer prevention (categorical outcomes for individuals with population effects 
identified as relative risk). General limitations to this assessment of benefit and risk of vitamin D 
are that our findings may not be generalizable to particularly vulnerable subgroups of the 
population, such as patients of high age in critical care or those with hypersensitivity to vitamin 
D (e.g. sarcoidosis), as high-dose vitamin D trials are either ongoing or have not been performed 
in such populations. Also, we used the equivalent daily dose of vitamin D for intermittent dosing 
of weekly or monthly applications, which may over-estimate the per day dose to some 
degree[130]. However, the benefit and risk assessment from RCTs is similar if achieved 
25(OH)D levels are plotted instead of dose. Finally, we have selected observational data on the 
benefit of vitamin D, which largely, but may not fully represent the available literature. 
 
The IOM established a UL for vitamin D based on hypercalcemia as the critical effect and two 
studies have been cited as a matter of concern by the IOM, (1) the trial by Honkanen et al. 
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included in our risk assessment and (2) the trial by Narang et al. not included in our risk 
assessment as 25(OH)D levels were not available.  Notably, in the trial by Honkanen et al. the 
hypercalcemia observed is not relevant to the risk assessment of vitamin D because it occurred in 
the institutionalized control group with a mean serum 25(OH)D concentration of 10.4 
nmol/l[45]. Both groups of hospitalized and community-dwelling older adults showed no 
increase in serum calcium levels with 1800 IU vitamin D per day.   The trial of Narang et al. [68] 
that IOM relied upon to identify a no observed adverse effect level of 2400 IU vitamin D per day 
and establish a UL of 2,000 IU per day is now considered unreliable because several other more 
recent clinical trials included in our risk analysis have failed to confirm the occurrence of 
hypercalcemia at intakes of up to more than ten-fold those used in that study[118].  
Consequently, the 2007 risk assessment concluded that the UL could be safely adjusted upward 
to 10,000 IU [22].    Nonetheless, in general the causal relationship between excessive vitamin D 
intake and hypercalcemia is well established [22]but the dose that will result in this critical effect 
is higher than any used in the RCTs and prospective cohort studies that have been reported.  
Thus, the flat-line relationship of serum calcium to the other parameters in Figures 1A and 1B 
does not contradict the identification of hypercalcemia as the critical effect for excess vitamin D; 
it indicates only that the effect must occur at higher 25(OH)D concentrations and with higher 
oral intakes of vitamin D. 
As calcium absorption is improved with higher serum 25(OH)D levels[131, 132], future studies 
may need to evaluate whether current calcium intake recommendations with higher doses of 
vitamin D beyond 2000 IU per day are safe or require downward adjustment [131]. If dietary 
calcium is a threshold nutrient, as suggested by Dr. Heaney[119], then that threshold for optimal 
calcium absorption may be at a lower calcium intake when vitamin D status is adequate. 
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Regarding relevant endpoints, a downward adjustment of calcium intake recommendations is 
supported by the recent meta-analysis on non-vertebral fracture prevention where fracture 
prevention at a vitamin D dose greater than 480 IU per day was independent of additional 
calcium supplementation. Also two recent epidemiologic studies suggested that both PTH 
suppression[132] and hip bone density[133] may only depend on a higher calcium intake if 
serum 25-hydroxyvitamin D levels are very low.  
 
 
Summary 
In this analysis we examined benefits (reductions in fractures and falls) and risks 
(hypercalcemia) as a function of vitamin D intake and serum concentrations of 25(OH)D in 
randomized trials.  We also used non randomized evidence to evaluate the levels of 25(OH)D at 
which benefits (reductions in colorectal cancer and cardiovascular disease) and risks 
(hypercalcemia and nephrolithiasis) are observed.   We found no pattern of evidence to suggest 
that risks are elevated within the ranges of serum 25(OH)D or oral vitamin intake  related to 
increased benefits ( 75 – 110 nmol/l).  Instead, the reliable evidence that excess vitamin D can 
cause hypercalcemia in generally healthy adults comes from daily intakes of vitamin D greater 
than 100,000 IU or serum 25(OH)D exceeding 240 nmol/L, which are far higher than those 
necessary to achieve the benefits.  The evidence from randomized trials suggests that the dose of 
vitamin D supplement needed to bring the large majority of persons to the range of optimal 
serum 25(OH)D, may be in the range of 1800 to 4000 IU/day.  Further work is needed, taking 
into account subject and environment factors, to better define the doses that will achieve the 
optimal blood levels in the large majority of the population. 
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Figure 1: Evidence from controlled RCTs: Trend-plots on benefit (fall and non-vertebral 
fracture prevention) and risk (mean achieved serum calcium levels) by dose of vitamin D and 
achieved 25(OH)D levels  
 
Figure 1A – by dose of vitamin D 
 
Figure 1B – by achieved 25(OH)D level 
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Legend Figure 1:  
Black circles represent relative risks (RRs) from 12 double-blind RCTs on vitamin D 
supplementation and non-vertebral fracture risk as summarized in a 2009 meta-analysis 
(Bischoff-Ferrari et al; Archives of Internal Medicine 2009[1]). Trendline is based on series of 
effect sizes (circles). For any non-vertebral fractures, anti-fracture efficacy increased 
significantly with higher received dose (meta-regression: Beta = - 0.0007; p = 0.003; Figure 1 
A) and higher achieved 25-hydroxyvitamin D levels (meta-regression: Beta = - 0.005; p = 0.04; 
Figure 1 B). 
Black triangles represent relative risks (RRs from 8 double-blind RCTs on vitamin D 
supplementation and fall risk as summarized in a 2009 meta-analysis (Bischoff-Ferrari et al; in 
press British Medical Journal[2]). Trendline is based on series of effect sizes (triangles). A 
meta-regression, which included 2426 individuals from 8 RCTs, indicated a significant inverse 
relationship between higher treatment dose and the risk of sustaining at least one fall (Beta-
estimate for dose: 700 IU or higher compared to less = - 0.337; p = 0.02; Figure 1 A).  
A meta-regression, which included 1447 individuals from 6 RCTs with reported 25(OH)D levels, 
indicated a significant inverse relationship between higher achieved 25(OH)D level in the 
treatment group and the risk of sustaining at least one fall (Beta-estimate for a 25(OH)D of 60 
nmol/l or higher compared to lower  = - 0.586; p = 0.005; Figure 1 B).  
Grey squares represent mean calcium levels in the treatment group from 25 vitamin D 
supplementation trials (28 data points; one trial with separate report from community-dwelling 
and hospitalized older individuals[45]). Trendline is based on series of mean serum calcium 
levels (grey squares). The doses of vitamin D applied in these trials ranged from 400 to 100’000 
IU vitamin D per day. There was flat trend line for mean serum calcium levels with higher dose 
of vitamin D (Figure 1 A) and higher achieved 25-hydroxyvitamin D levels (Figure 1 B).  
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Figure 2: Trend-plots on benefit from observational studies (cardiovascular disease prevention 
and colorectal cancer prevention) and risk (case reports of hypercalcemia) by achieved 25(OH)D 
level 
 
 
Legend Figure 2: 
Dashed lines relate to data from epidemiologic studies on the RR of incident hypertension[4], 
all-cause[90] and cardiovascular[90] mortality and colorectal cancer [91] based on categories of 
median 25-hydroxyvitamin D levels. For colorectal cancer, we included a quantitative meta-
analysis of 5 studies[91]. Based on this summary of non-skeletal endpoints of public health 
significance, there was a dose-response of better health status with higher median 25(OH)D 
levels. By visual inspection, the desirable median serum 25(OH)D level to be achieved for all 
endpoints was approximately 100 nmol/l. 
The solid grey diamonds relate to 24 case-reports of hypercalcemia with corresponding 25(OH)D 
levels. 22 of 24 cases of hypercalcemia were reported at 25(OH)D levels beyond 240 nmol/l 
25(OH)D.   
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Figure 3: Dose of vitamin D and achieved 25(OH)D levels based on RCTs with a duration of at 
least 4 weeks 
 
Figure 3 A: Lower dose trials (double-blind fall and fracture RCTs) 
 
This graph summarizes data from identified RCTs (as illustrated in Figure 1) with oral doses of 
vitamin D of less than 10,000 IU vitamin D per day and a treatment duration of at least 4 weeks. 
Dots either represent the mean 25(OH)D level from a single trial or the mean and the range of 
several trials.  
There were 3 RCTs with 400 IU vitamin D per day with a mean increase in 25(OH)D levels to 
56.7 nmol/l (range: 44 to 64 nmol/l) after a mean treatment duration of 653 days (range: 140 to 
1148 days). The trial with 700 IU vitamin D and achieved mean serum levels close to 100 nmol/l 
may be an outlier due to the high starting levels documented in the trial (84 nmol/l in men and 72 
nmol/l in women age 65 and older[26]). There were 9 RCTs for 800 IU per day with a mean 
increase in 25(OH)D levels to 75 nmol/l (range: 60 to 105 nmol/l) after a mean treatment 
duration of 697 days (range: 56 to 1680 days).  
There were 7 RCTs with 2000 IU vitamin D per day with a mean increase in 25(OH)D levels to 
87 nmol/l (range: 71 to 103 nmol/l) after a mean treatment duration of 146 days (range: 42 to 365 
days).There were 3 RCTs for 4000 IU per day with a mean increase in 25(OH)D levels to 120 
26 
 
nmol/l (range: 85.5 to 160 nmol/l) after a mean treatment duration of 168 days (range: 56 to 365 
days). And there were 4 trials with a treatment dose between 5720 and 7600 IU vitamin D per 
day with a mean increase in 25(OH)D levels to 128 nmol/l (range: 120-147 nmol/l). 
From this summary of available dose-response data from RCTs, most trials among healthy 
younger and older adults reached a mean value in the target range of 75 to 110 nmol/l with 1800 
IU to 4000 IU vitamin D3 per day treated for at least 42 days.  
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